Synergistic bacterial compositions and methods of production and use thereof

Patent metadata

Field	Value
Publication number	US-10864235-B2
Application number	US-201816223008-A
Country	US
Kind code	B2
Filing date	Dec 17, 2018
Priority date	Nov 23, 2012
Publication date	Dec 15, 2020
Grant date	Dec 15, 2020

Abstract

Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

First claim

What is claimed is:

1. A composition comprising a first species of isolated bacterium and a second species of isolated bacterium, wherein the first species is Clostridium innocuum and the second species is Clostridium orbiscindens , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548, wherein the first species and the second species are capable of inhibiting C. difficile growth as measured by a CivSim assay, and wherein the composition further comprises an enteric coating.

2. The composition of claim 1 , wherein the first species and the second species are capable of inhibiting C. difficile growth in a CivSim assay with a confidence interval of >99% (++++).

3. The composition of claim 1 , wherein the first species and/or the second species is capable of forming a spore.

4. The composition of claim 3 , wherein the first species and/or the second species is in the form of spores.

5. The composition of claim 1 , formulated for populating the gastrointestinal tract of a subject.

6. The composition of claim 1 , wherein the first species and the second species are lyophilized.

7. A kit comprising in one or more containers the composition of claim 1 .

8. A pharmaceutical formulation comprising the composition of claim 1 .

9. The pharmaceutical formulation of claim 8 , further comprising an additional agent selected from an anti-bacterial agent, anti-fungal agent, anti-viral agent, anti-parasitic agent, or combinations thereof.

10. The composition of claim 1 , wherein the Clostridium innocuum comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 534.

11. The composition of claim 1 , wherein the Clostridium innocuum comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 534.

12. The composition of claim 1 , wherein the Clostridium innocuum comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 534.

13. The composition of claim 1 , wherein the Clostridium innocuum comprises the 16S rDNA sequence set forth in SEQ ID NO: 534.

14. The composition of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 548.

15. The composition of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 548.

16. The composition of claim 1 , wherein the Clostridium orbiscindens comprises the 16S rDNA sequence set forth in SEQ ID NO: 548.

17. The pharmaceutical formulation of claim 8 , formulated for oral administration.

18. The pharmaceutical formulation of claim 8 , further comprising a pharmaceutically acceptable excipient.

Assignees

• Seres Therapeutics Inc

Inventors

• Henn Matthew R
• Von Maltzahn Geoffrey
• D'Onofrio Anthony Mario
• Litcofsky Kevin Daniel
• Berry David Arthur
• Cook David N
• Afeyan Noubar B
• Aunins John Grant

Classifications

• A61K35/74 Primary

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title

• A23P10/30

  Encapsulation of particles, e.g. foodstuff additives · CPC title

• A23L33/127

  Antibiotics · CPC title

• A23L33/135

  Bacteria or derivatives thereof, e.g. probiotics · CPC title

• A61K38/13

  Cyclosporins · CPC title